Novel Radiotherapy Approaches in Stage IV NSCLC
This education activity is aimed at updating participants with the latest available data regarding the use of radiotherapy for patients with metastatic lung cancer. The primary focus will be on the use of radiotherapy with curative intent for patients with limited metastatic disease.
Presentation format is case-based with a plan to discuss the literature to support medical decision making as well as to provide technical details about strategies for radiation delivery in this setting. Topics covered include review of data to support the use of consolidative thoracic radiation as well as data to support SBRT for patients with oligometastatic disease.
The session also covers emerging data about the use of radiation therapy for patients with metastatic lung cancer who develop recurrent or progressive disease at a limited number of metastatic sites. We discuss opportunities and risks of combination treatment with systemic therapies including immunotherapy, oral targeted therapies and cytotoxic chemotherapy. Finally, this activity discusses ongoing clinical trials and encourage participation in clinical studies as part of ongoing evaluation about the use of curative intent radiation therapy for patients with metastatic lung cancer.
The activity is designed to meet the interests of practicing radiation oncologists, radiation oncology residents, medical oncologists and surgeons.
Upon completion of this activity, participants should be able to do the following:
- Identify patients with Stage IV NSCLC who may benefit from consolidative thoracic radiotherapy.
- Explain rationale for aggressive treatment of patients with oligometastatic NSCLC.
- Discuss risks of combining radiation therapy with novel systemic therapies in the treatment of Stage IV NSCLC.
Puneeth Iyengar, MD, is employed at UT Southwestern Medical Center and has no financial relationships with a commercial interest.
Bradford Perez, MD, is employed at H. Lee Moffitt Cancer Center and has an investment interest from BMS.
Christine Bestvina, MD, is employed at Northwestern Medicine, University of Chicago and has an investment interest from Abbvie, AstraZeneca, Genentech, Pfizer, Seattle Genetics and Tajeda.
All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.50 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.50 Certificate of AttendanceThis activity was designated for 1.50 AMA PRA Category 1 Credit™.